Company intelligence / Profile preview

Ambrosia Biosciences

Boulder, Colorado, United Statesambrosiaofficial.com ↗

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Ambrosia Biosciences is developing orally delivered small-molecule therapies targeting GLP‑1 and related pathways for obesity and metabolic diseases. The company aims to present its first preclinical data sets by the end of 2025 and file its first IND with the FDA around the end of 2026. No clinical results are available yet as programs are in preclinical development.

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Small molecule
Industry: Biotech

Partnerships

Merck (investor via M Ventures)

Beyond the preview

Go deeper on Ambrosia Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ambrosia Biosciences.

Explore the full profile